Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $22.7600 (-0.31%) ($22.2100 - $22.9200) on Mon. Sep. 10, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.64% (three month average) | RSI | 62 | Latest Price | $22.7600(-0.31%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.3% a day on average for past five trading days. | Weekly Trend | ADMS advances 1.7% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(21%) IBB(19%) ONLN(19%) XOP(18%) IWM(16%) | Factors Impacting ADMS price | ADMS will decline at least -1.32% in a week (0% probabilities). VIXM(-10%) UNG(-10%) BNDX(-9%) UUP(-8%) VXX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.32% (StdDev 2.64%) | Hourly BBV | 0 () | Intraday Trend | -0.7% | | | |
|
5 Day Moving Average | $22.79(-0.13%) | 10 Day Moving Average | $22.75(0.04%) | 20 Day Moving Average | $22.58(0.8%) | To recent high | -18.3% | To recent low | 4.5% | Market Cap | $644m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |